Skip to Content

Aminocaproic acid Disease Interactions

There are 3 disease interactions with aminocaproic acid:

Major

Aminocaproic Acid (Includes Aminocaproic acid) ↔ Myopathy

Severe Potential Hazard, Low plausibility

Applies to: Myopathy

Skeletal muscle toxicity ranging from mild myalgia to rhabdomyolysis has been reported rarely during prolonged administration of aminocaproic acid. Therapy with aminocaproic acid should be administered cautiously in patients with or predisposed to myopathy. Clinical monitoring of muscle enzymes (particularly CPK) are recommended.

References

  1. "Product Information. Amicar (aminocaproic acid)." Immunex Corporation, Seattle, WA.
Major

Aminocaproic Acid (Includes Aminocaproic acid) ↔ Renal Dysfunction

Severe Potential Hazard, High plausibility

Applies to: Renal Dysfunction

Aminocaproic acid is primarily eliminated by the kidney. Approximately 65% of aminocaproic acid is excreted unchanged in the urine. Serum concentrations of aminocaproic acid can be increased in patients with renal impairment. Therapy with aminocaproic acid should be administered with extreme caution in patients with upper urinary tract bleeding. Glomerular capillary thrombosis or clots in the renal pelvis and ureters have occurred in patients with upper urinary tract bleeding during aminocaproic acid therapy. Clinical monitoring of renal function, clot lysis activity and fibrinolytic determinants (profibrinolysin, fibrinolysin and anti-fibrinolysin) is recommended.

References

  1. "Product Information. Amicar (aminocaproic acid)." Immunex Corporation, Seattle, WA.
Major

Aminocaproic Acid (Includes Aminocaproic acid) ↔ Thrombohemorrhagic Disorders

Severe Potential Hazard, High plausibility

Applies to: Thrombotic/Thromboembolic Disorder, Disseminated Intravascular Coagulation

The use of aminocaproic acid is contraindicated in patients with active intravascular clotting. Aminocaproic acid should not be used in the presence of disseminated intravascular coagulation (DIC) without concomitant administration of heparin. Aminocaproic acid inhibits plasminogen activators and, to a lesser extent, plasmin activity, resulting in decreased fibrinolysis. Clinical monitoring of clot lysis activity and fibrinolytic determinants (profibrinolysin, fibrinolysin and anti-fibrinolysin) is recommended.

References

  1. "Product Information. Amicar (aminocaproic acid)." Immunex Corporation, Seattle, WA.

aminocaproic acid drug Interactions

There are 12 drug interactions with aminocaproic acid

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide